These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35370887)

  • 21. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
    Gold R; Giovannoni G; Phillips JT; Fox RJ; Zhang A; Meltzer L; Kurukulasuriya NC
    Mult Scler; 2015 Jan; 21(1):57-66. PubMed ID: 24990854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
    De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
    Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis.
    Dupuy SL; Tauhid S; Hurwitz S; Chu R; Yousuf F; Bakshi R
    Neurol Ther; 2016 Dec; 5(2):215-229. PubMed ID: 27744504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
    Matolcsi J; Rózsa C
    Ideggyogy Sz; 2015 Jan; 68(1-2):7-14. PubMed ID: 25842911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.
    Bomprezzi R
    Ther Adv Neurol Disord; 2015 Jan; 8(1):20-30. PubMed ID: 25584071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.
    Phillips JT; Selmaj K; Gold R; Fox RJ; Havrdova E; Giovannoni G; Abourjaily H; Pace A; Novas M; Hotermans C; Viglietta V; Meltzer L
    Int J MS Care; 2015; 17(5):236-43. PubMed ID: 26472945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM.
    Giovannoni G; Gold R; Kappos L; Arnold DL; Bar-Or A; Marantz JL; Yang M; Lee A
    Mult Scler J Exp Transl Clin; 2016; 2():2055217316634111. PubMed ID: 28607719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
    Zivadinov R; Bagnato F; Nasuelli D; Bastianello S; Bratina A; Locatelli L; Watts K; Finamore L; Grop A; Dwyer M; Catalan M; Clemenzi A; Millefiorini E; Bakshi R; Zorzon M
    J Neurol Sci; 2004 Aug; 223(2):185-93. PubMed ID: 15337621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.
    Koulinska I; Riester K; Chalkias S; Edwards MR
    Clin Ther; 2018 Dec; 40(12):2021-2030.e1. PubMed ID: 30447891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study.
    Zivadinov R; Bergsland N; Carl E; Ramasamy DP; Hagemeier J; Dwyer MG; Lizarraga AA; Kolb C; Hojnacki D; Weinstock-Guttman B
    J Clin Med; 2019 Mar; 8(3):. PubMed ID: 30870983
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A semiautomated measure of whole-brain atrophy in multiple sclerosis.
    Bermel RA; Sharma J; Tjoa CW; Puli SR; Bakshi R
    J Neurol Sci; 2003 Apr; 208(1-2):57-65. PubMed ID: 12639726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND.
    Repovic P; Robertson D; Kresa-Reahl K; Cohan SL; Su R; Avila R; Koulinska I; Mendoza JP
    Neurol Ther; 2021 Jun; 10(1):169-182. PubMed ID: 33225410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
    Ernst FR; Barr P; Elmor R; Wong SL
    Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Blair HA
    Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
    Zivadinov R; Kresa-Reahl K; Weinstock-Guttman B; Edwards K; Burudpakdee C; Bergsland N; Dwyer MG; Khatri B; Thangavelu K; Chavin J; Mandel M; Cohan S
    J Comp Eff Res; 2019 Apr; 8(5):305-316. PubMed ID: 30754997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.
    Hardmeier M; Wagenpfeil S; Freitag P; Fisher E; Rudick RA; Kooijmans-Coutinho M; Clanet M; Radue EW; Kappos L;
    Arch Neurol; 2003 Dec; 60(12):1736-9. PubMed ID: 14676048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.